У нас вы можете посмотреть бесплатно Apr 04 2025 This Week in Cardiology или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Trials from the 2025 American College of Cardiology scientific sessions, including the WARRIOR, PROTECT TAVI, DAPATAVI, and SOUL are reviewed by John Mandrola, MD This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Thank you Comments II WARRIOR Women’s IschemiA TRial to Reduce Events In Non-ObstRuctive CAD • Keep Fighting INOCA After Neutral WARRIOR Trial https://www.medscape.com/viewarticle/... III Cerebral Embolic Protection in TAVI • PROTECT TAVI https://www.nejm.org/doi/full/10.1056... • PROTECTED TAVR https://www.nejm.org/doi/full/10.1056... • Instrumental Variables in Randomized Trials https://evidence.nejm.org/doi/10.1056... IV DAPATAVI • SGLT2 Inhibitors Progressing to New Standard After TAVI https://www.medscape.com/viewarticle/... • Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation https://www.nejm.org/doi/full/10.1056... V SOUL Study of Oral Semaglutide and CV outcomes in Diabetes • Oral GLP-1 Receptor Agonist Reduces CV Risk https://www.medscape.com/viewarticle/... • Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes https://www.nejm.org/doi/full/10.1056... You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-h... Questions or feedback, please contact [email protected]